References
- Xu L, Zhao WL, Xiong SM, et al. Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia 2001;15:1359–1368.
- González M, Barragán E, Bolufer P, et al. Pre-treatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML/ RARα isoforms: a study of the PETHEMA Group. Br J Haematol 2001;18:2332–2338.
- Park TS, Kim JS, Song J, et al. Acute promyelocytic leukemia with insertion of PML exon 7a and partial deletion of exon 3 of RARA: a novel variant transcript related to aggressive course and not detected with real-time polymerase chain reaction analysis. Cancer Genet Cytogenet 2009;188:103–107.
- Barragán E, Bolufer P, Martín G, et al. Identification of two atypical PML-RAR(alpha) transcripts in two patients with acute promyelocytic leukemia. Leuk Res 2002;26:439–442.
- Chillón MC, González M, García-Sanz R, et al. Two new 3’ PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. Genes Chromosomes Cancer 2000;27:35–43.
- Castaigne SY, Lefebvre PH, Chomienne CH, et al. Effectiveness and parmacokinetices of low-dose all-trans retinoic acid(25mg/m2) in acute promyelocytic leukemia. Blood 1993;82:3560–3563.
- Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukmia. Leukemia 1996;10:825–828.
- Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia 2003;17:2318–2357.